AMPH (Amphastar Pharmaceuticals) Scaled Net Operating Assets: 0.72 (As of Mar. 2026)


AMPH Amphastar Pharmaceuticals Inc AMPH
83 GF Score
Price $21.42
GF Value $48.78
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Scaled Net Operating Assets?

Amphastar Pharmaceuticals AMPH +1.93% 83 Scaled Net Operating Assets is 0.72 as of Mar. 2026. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.78 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Amphastar Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was $1,356.2 Mil. Amphastar Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was $188.4 Mil. Amphastar Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $1,629.3 Mil. Therefore, Amphastar Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.72.


Amphastar Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Scaled Net Operating Assets Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.68 1.36 0.77 0.74

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.73 0.72 0.70 0.72

AMPH vs ETON, ESPR, BIOA: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Scaled Net Operating Assets falls into.


AMPH
83GF Score
Amphastar Pharmaceuticals Inc AMPH
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Amphastar Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(1346.487-184.492)/1577.47
=0.74

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1629.299 - 282.812
=1346.487

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=840.494 - 646.433 - 9.569
=184.492

Amphastar Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(1356.211-188.393)/1629.299
=0.72

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1648.162 - 291.951
=1356.211

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=874.771 - 675.002 - 11.376
=188.393

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.72 mean?
Amphastar Pharmaceuticals (AMPH) has a Scaled Net Operating Assets of 0.72 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Scaled Net Operating Assets too high?
Amphastar Pharmaceuticals' current Scaled Net Operating Assets is 0.72. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Scaled Net Operating Assets compare to ETON and ESPR?
Amphastar Pharmaceuticals' Scaled Net Operating Assets of 0.72 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Scaled Net Operating Assets is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $21.42 — trading 56.1% below its estimated fair value. The current Scaled Net Operating Assets is 0.72. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Scaled Net Operating Assets is 0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $21.42 is trading 56.1% below its estimated GF Value™ of $48.78. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Scaled Net Operating Assets: 0.72
  • GF Value™: $48.78 vs. price of $21.42 (56.1% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score

Get the complete analysis for AMPH

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.42
Price
$48.78
GF Value